The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2017 | Promising CLL & FL data from ICML 2017: BGB-3111 and obinituzumab
Susan O’Brien, MD from UC Irvine Health, Orange County, CA shares her stand-out abstract presented at the International Conference on Malignant Lymphoma (ICML) 2017, Lugano, Switzerland. Dr O’Brien describes the convincing and positive data,presented by Constantine Tam, which demonstrated the benefit of combining the second-generation BTK inhibitor, BGB-3111, and anti-CD20 agent, obinutuzumab, in the treatment of follicular lymphoma and chronic lymphocytic leukemia.
